(Alliance News) - Recordati Spa announced Monday the appointment of Milan Zdravkovic as Executive Vice President of Research & Development.

"This announcement confirms Recordati's continued commitment to accessible innovation," the company said. Milan Zdravkovic, a Danish national, brings a wealth of experience to his new role, with an impressive track record in developing innovative solutions and leading R&D teams in the pharmaceutical industry. His expertise covers a wide range of therapeutic areas, including those related to diabetes, obesity, immunology, hematology and infectious diseases, with experience in both rare and non-rare diseases."

With 25 years of experience in the life-science industry, Zdravkovic has worked at pharmaceutical and biotechnology companies such as Novo Nordisk, SOBI-Swedish Orphan Biovitrum and SNIPR Biome, holding positions of increasing responsibility such as Head of R&D and Chief Medical Officer.

Robert Koremans, CEO of Recordati, said, "I am delighted to welcome Milan to our company. His extensive therapeutic knowledge, experience in rare diseases, and global leadership will be invaluable in strengthening our R&D teams. Milan will play a key role in accelerating our life cycle management program and achieving our business goals."

Commenting on his appointment, Milan Zdravkovic said, "Recordati has demonstrated a solid track record of building a profitable and sustainable business with a deep understanding of patients' unmet needs. I am thrilled to be able to contribute to the company's rich 100-year heritage and, at the same time, feel honored and excited to lead the R&D efforts. I look forward to starting this collaboration with my colleagues to contribute to the future success of the company."

Raffaele Sabia, who has been instrumental in creating and leading the current R&D and Medical Affairs department, has been appointed Chief Medical Officer, heading the Global Medical Office that includes Medical Affairs, Health Economics & Outcome Research, Patient Advocacy and Patient Safety. Raffaele will also lead the Recordati Rare Diseases Foundation, aiming to contribute to its mission of making a positive impact in the health sector and the community at large.

"I would like to thank Raffaele for his commitment to building a strong foundation for R&D at Recordati and look forward to seeing the positive impact his expertise can have in his new role," said Rob Koremans.

Recordati's stock is down 0.6 percent at EUR45.00 per share.

By Giuseppe Fabio Ciccomascolo, Alliance News senior reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.